GO:0090291 negative regulation of osteoclast proliferation: Signaling Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090291 describes any process that decreases the rate, frequency, or extent of osteoclast multiplication, thereby limiting expansion of the osteoclast population.
• Osteoclast proliferation is driven by M-CSF/c-Fms signaling and is restrained by negative regulators such as SHIP1, which acts through Akt-dependent changes in D-type cyclins and p27.
• Lipocalin-2 deficiency promotes proliferation and differentiation of osteoclast precursors via c-Fms and NF-kappaB, illustrating how secreted factors can relieve negative regulation.
• Glucocorticoid signaling and metabolic pathways are established systemic modulators of skeletal cell fate and osteoclast biology.
• Hippo-YAP/TAZ signaling is an emerging pathway in musculoskeletal disorders that can influence skeletal cell proliferation and differentiation.
• CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of candidate negative regulators of osteoclast proliferation.
Description
Osteoclasts are multinucleated bone-resorbing cells whose numbers are set by the balance between precursor proliferation, differentiation, and survival. GO:0090291, negative regulation of osteoclast proliferation, captures the biological processes that decrease the rate, frequency, or extent of osteoclast multiplication, thereby preventing uncontrolled expansion of the osteoclast population. This term is distinct from negative regulation of osteoclast differentiation, because it specifically concerns the multiplication or reproduction of osteoclasts rather than their acquisition of a resorptive phenotype.
negative regulation of osteoclast proliferation At A Glance
| GO ID | GO:0090291 |
|---|---|
| GO term | negative regulation of osteoclast proliferation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the rate, frequency, or extent of osteoclast multiplication or reproduction, limiting expansion of the osteoclast cell population. |
| Biological context | Bone remodeling and skeletal homeostasis, where osteoclast numbers must be tightly controlled. |
| Representative negative regulator | SHIP1, which negatively regulates osteoclast precursor proliferation via Akt-dependent alterations in D-type cyclins and p27. |
| Representative relieving factor | Lipocalin-2 deficiency promotes proliferation and differentiation of osteoclast precursors via c-Fms and NF-kappaB. |
| Related signaling | M-CSF/c-Fms, Akt, NF-kappaB, glucocorticoid signaling, and Hippo-YAP/TAZ. |
What Is GO:0090291?
In practical terms, GO:0090291 refers to any cellular or molecular process that lowers the rate, frequency, or extent of osteoclast multiplication or reproduction, resulting in a smaller osteoclast cell population. This includes signals that slow cell-cycle progression, reduce precursor proliferation, or otherwise limit the expansion of osteoclast lineage cells.
Why Is negative regulation of osteoclast proliferation Important in Cell Biology?
Negative regulation of osteoclast proliferation is central to bone homeostasis because excessive osteoclast numbers drive pathological bone resorption, while insufficient osteoclast activity causes osteopetrosis. Understanding the molecular brakes on osteoclast precursor proliferation therefore informs both bone biology and therapeutic strategies for skeletal disease.
• Controls osteoclast population size and thereby the overall rate of bone resorption.
• Prevents excessive osteoclast expansion that can contribute to inflammatory and metabolic bone loss.
• Provides mechanistic insight into how cytokines and growth factors tune osteoclast precursor proliferation.
• Links cell-cycle regulators such as D-type cyclins and p27 to skeletal cell fate.
• Connects systemic signals, including glucocorticoids and metabolic cues, to osteoclast biology.
• Highlights emerging pathways such as Hippo-YAP/TAZ in musculoskeletal disorders.
• Supports development of CRISPR models to test causal roles of candidate negative regulators.
• Helps interpret bone phenotypes in genetically modified mouse models.
• Informs research on osteoclast precursors as a targetable compartment in bone disease.
• Provides a framework for comparing negative regulation of proliferation with negative regulation of differentiation.
What Happens During negative regulation of osteoclast proliferation?
Osteoclast precursor proliferation and its brakes
In simple terms: Osteoclast precursors normally multiply when growth factors tell them to, and negative regulation puts the brakes on this multiplication.
Osteoclast precursors proliferate in response to growth-factor signaling, and negative regulation of osteoclast proliferation refers to processes that decrease the rate, frequency, or extent of this multiplication. SHIP1 is a well-characterized negative regulator that reduces osteoclast precursor proliferation through Akt-dependent changes in D-type cyclins and p27.
M-CSF/c-Fms and NF-kappaB signaling
In simple terms: A key growth-factor pathway can push precursors to multiply, and factors that interfere with it can slow proliferation.
M-CSF signaling through c-Fms is a major driver of osteoclast precursor proliferation, and modulation of c-Fms expression or downstream NF-kappaB activation can alter proliferative output. Deficiency of Lipocalin-2 promotes proliferation and differentiation of osteoclast precursors via regulation of c-Fms expression and nuclear factor-kappa B activation, showing how loss of a factor can relieve negative regulation.
Cell-cycle control by Akt, D-type cyclins, and p27
In simple terms: Negative regulators can act by changing the molecules that control whether a cell divides.
SHIP1 negatively regulates proliferation of osteoclast precursors via Akt-dependent alterations in D-type cyclins and p27, directly linking a negative regulatory process to cell-cycle machinery. This illustrates that negative regulation of osteoclast proliferation can be executed through changes in cyclin expression and cyclin-dependent kinase inhibitor levels.
Systemic and metabolic modulation
In simple terms: Hormones and cellular metabolism can also influence how many osteoclasts are produced.
Glucocorticoid signaling is an established regulator of bone biology and can influence skeletal cell populations. Metabolic regulation of skeletal cell fate and function further indicates that nutrient and energy pathways can modulate osteoclast lineage behavior.
Emerging pathways: Hippo-YAP/TAZ
In simple terms: Newer signaling pathways are being recognized as additional controls on skeletal cell proliferation.
The Hippo-YAP/TAZ signaling pathway has an emerging role in musculoskeletal disorders and can influence skeletal cell proliferation and differentiation. This pathway is therefore a candidate context for negative regulation of osteoclast proliferation, although direct evidence in osteoclasts continues to be investigated.
Key Genes Involved in GO:0090291 negative regulation of osteoclast proliferation
The following genes and proteins have documented roles in osteoclast proliferation, its negative regulation, or related skeletal cell fate control.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SHIP1 (INPP5D) | Negatively regulates osteoclast precursor proliferation via Akt-dependent changes in D-type cyclins and p27 | Core negative regulator for mechanistic studies of GO:0090291 |
| CSF1R (c-Fms) | Receptor for M-CSF; drives osteoclast precursor proliferation | Target for modulating proliferative signaling |
| LCN2 (Lipocalin-2) | Its deficiency promotes proliferation and differentiation of osteoclast precursors via c-Fms and NF-kappaB | Secreted factor that can relieve negative regulation |
| NFKB1/NF-kappaB | Downstream mediator of c-Fms signaling in osteoclast precursors | Links inflammatory signaling to precursor proliferation |
| AKT1 | Kinase whose activity is altered by SHIP1 to control D-type cyclins and p27 | Central node in negative regulation of proliferation |
| CCND1 (Cyclin D1) | D-type cyclin affected by Akt-dependent regulation in osteoclast precursors | Cell-cycle readout for proliferation assays |
| CDKN1B (p27) | Cyclin-dependent kinase inhibitor altered by SHIP1-Akt signaling | Marker of proliferative arrest |
| NR3C1 (Glucocorticoid receptor) | Mediates glucocorticoid signaling in bone biology | Systemic modulator of skeletal cell populations |
| YAP1 | Hippo-YAP/TAZ pathway effector in musculoskeletal disorders | Emerging candidate in skeletal cell proliferation |
| WWTR1 (TAZ) | Hippo-YAP/TAZ pathway effector in musculoskeletal disorders | Emerging candidate in skeletal cell proliferation |
| FOXF1 | Knockdown promotes BMSC osteogenesis via Wnt/beta-catenin and prevents ovariectomy-induced bone loss | Example of genetic manipulation altering skeletal cell fate |
| CTNNB1 (beta-catenin) | Wnt/beta-catenin pathway involved in bone formation and skeletal cell fate | Pathway context for bone remodeling studies |
| M-CSF (CSF1) | Growth factor ligand driving osteoclast precursor proliferation | Stimulus used in osteoclast proliferation assays |
| RANKL (TNFSF11) | Cytokine central to osteoclast differentiation | Context for distinguishing proliferation from differentiation |
| OPG (TNFRSF11B) | Decoy receptor regulating RANKL activity | Context for osteoclast biology |
How Is negative regulation of osteoclast proliferation Regulated?
Negative regulation of osteoclast proliferation is itself regulated at multiple levels. SHIP1 acts through Akt-dependent changes in D-type cyclins and p27 to restrain precursor proliferation. M-CSF/c-Fms signaling and NF-kappaB activation can promote proliferation, and factors such as Lipocalin-2 can modulate this axis. Systemic signals including glucocorticoids influence bone biology and skeletal cell populations, while metabolic pathways shape skeletal cell fate and function. The Hippo-YAP/TAZ pathway represents an additional layer of regulation relevant to musculoskeletal disorders.
negative regulation of osteoclast proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SHIP1 (INPP5D) | Osteoclast precursor proliferation and bone resorption | Knockout and point-mutation models in osteoclast precursors |
| LCN2 (Lipocalin-2) | Osteoclast precursor proliferation via c-Fms and NF-kappaB | Knockout mouse and overexpression cell models |
| FOXF1 | Ovariectomy-induced bone loss and BMSC osteogenesis | Knockdown or knockout models in bone marrow stromal cells |
| NR3C1 (Glucocorticoid receptor) | Glucocorticoid signaling and bone biology | Conditional knockout and point-mutation models |
| YAP1/WWTR1 | Musculoskeletal disorders | Knockout and overexpression models in skeletal cells |
Bone loss and osteoclast-driven pathology
Excessive osteoclast proliferation and activity contribute to pathological bone resorption. Negative regulators such as SHIP1 restrain precursor proliferation, and their dysfunction could shift the balance toward bone loss. Models of ovariectomy-induced bone loss are used to study skeletal cell fate interventions, as shown for Foxf1 knockdown promoting BMSC osteogenesis.
Inflammatory and metabolic bone disease
Inflammatory signaling through NF-kappaB downstream of c-Fms can promote osteoclast precursor proliferation, and Lipocalin-2 deficiency enhances this process. Metabolic regulation of skeletal cell fate and function further links systemic metabolic states to bone cell behavior.
Glucocorticoid-associated skeletal changes
Glucocorticoid signaling is an established regulator of bone biology, and altered glucocorticoid tone can affect skeletal cell populations. Understanding how such signals intersect with negative regulation of osteoclast proliferation may clarify steroid-associated bone phenotypes.
Musculoskeletal disorders and emerging pathways
The Hippo-YAP/TAZ pathway has an emerging role in musculoskeletal disorders and can influence skeletal cell proliferation and differentiation. This pathway is therefore of interest for conditions in which osteoclast population size is dysregulated.
From negative regulation of osteoclast proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene a negative regulator of osteoclast proliferation? | CRISPR knockout in osteoclast precursor cell lines or primary precursors |
| Does a specific phosphorylation site in a regulator control its function? | Point-mutation knock-in of the phospho-site |
| Does a disease-associated variant alter negative regulation? | Knock-in of the variant allele |
| Where and when is the regulator expressed in osteoclast lineage cells? | Tagged knock-in with fluorescent or epitope tag |
| Does increased dosage of a regulator suppress proliferation? | Overexpression model in osteoclast precursors |
| Does loss of a secreted factor relieve negative regulation? | Knockout of the factor with proliferation assays |
How to Study the negative regulation of osteoclast proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cell proliferation assay | Rate of osteoclast precursor multiplication | Testing candidate negative regulators |
| Flow cytometry | Cell-cycle distribution and population expansion | Evaluating proliferative arrest |
| Immunoblotting | D-type cyclin and p27 protein levels | Linking Akt signaling to cell-cycle changes |
| NF-kappaB reporter assay | NF-kappaB activation downstream of c-Fms | Assessing inflammatory signaling in precursors |
| qPCR | c-Fms and osteoclast marker expression | Characterizing precursor state |
| CRISPR knockout | Loss-of-function effects on proliferation | Causal gene testing |
| Overexpression | Gain-of-function effects on proliferation | Testing dosage-sensitive regulators |
| Transcriptomics | Global gene expression changes | Identifying downstream pathways |
Proliferation assays
Osteoclast precursor proliferation can be measured by cell counting, DNA synthesis assays, or dye-dilution methods. These assays are used to determine whether a candidate gene decreases the rate, frequency, or extent of osteoclast multiplication, as demonstrated for SHIP1.
Cell-cycle analysis
Because negative regulation of osteoclast proliferation can act through cell-cycle machinery, analysis of D-type cyclins and p27 by immunoblotting or flow cytometry is informative. Such readouts link molecular changes to proliferative output.
Signaling pathway assays
Akt phosphorylation, NF-kappaB activation, and c-Fms expression can be assessed to define the signaling route through which a negative regulator acts. These assays help distinguish effects on proliferation from effects on differentiation.
Genetic and genomic approaches
CRISPR-based knockout, point mutation, knock-in, and overexpression enable causal testing of candidate genes. Transcriptomic and proteomic profiling can complement these models to identify downstream effectors of negative regulation.
How CRISPR Can Be Used to Study GO:0090291 negative regulation of osteoclast proliferation
Knockout
CRISPR knockout of a candidate gene in osteoclast precursors can test whether loss of that gene increases proliferation, which would support its role in negative regulation of osteoclast proliferation. This approach is exemplified by studies of SHIP1 in osteoclast precursors.
Point Mutation
Point-mutation models can dissect specific residues required for negative regulation, such as phosphorylation sites in signaling proteins. Such models help determine whether a particular modification is necessary for restraining osteoclast proliferation.
Knock-in
Knock-in of disease-associated variants or tagged alleles allows study of how specific genetic changes affect negative regulation of osteoclast proliferation. Tagged knock-ins also enable tracking of regulator expression in osteoclast lineage cells.
Overexpression
Overexpression of a candidate negative regulator can test whether increased dosage suppresses osteoclast precursor proliferation. This complements loss-of-function approaches and can reveal dosage-sensitive effects.
How EDITGENE Supports negative regulation of osteoclast proliferation Research
Researchers studying negative regulation of osteoclast proliferation-related genes often need to determine whether a candidate gene is causally involved in limiting osteoclast multiplication, and CRISPR-based models provide a direct way to test this. EDITGENE supports these studies with knockout, point-mutation, knock-in, overexpression cell models, and CRISPR library screening with bioinformatics.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of osteoclast proliferation research.
Frequently Asked Questions About negative regulation of osteoclast proliferation
What is GO:0090291 negative regulation of osteoclast proliferation?
GO:0090291 is a Gene Ontology biological process term defined as any process that decreases the rate, frequency, or extent of the multiplication or reproduction of osteoclasts, resulting in the expansion of an osteoclast cell population.
What genes are involved in negative regulation of osteoclast proliferation?
Documented genes include SHIP1 (INPP5D), which negatively regulates osteoclast precursor proliferation via Akt-dependent changes in D-type cyclins and p27, and LCN2 (Lipocalin-2), whose deficiency promotes precursor proliferation via c-Fms and NF-kappaB.
How is osteoclast proliferation negatively regulated?
Negative regulation can occur through signaling pathways such as SHIP1-Akt, which alters D-type cyclins and p27, or through modulation of M-CSF/c-Fms and NF-kappaB signaling.
Why is negative regulation of osteoclast proliferation important for bone health?
It limits osteoclast population size and thereby restrains bone resorption, helping maintain skeletal homeostasis.
What is the difference between negative regulation of osteoclast proliferation and differentiation?
Proliferation refers to multiplication of osteoclasts or their precursors, whereas differentiation refers to acquisition of the osteoclast phenotype; GO:0090291 specifically concerns proliferation.
Which signaling pathways control osteoclast precursor proliferation?
M-CSF/c-Fms, NF-kappaB, Akt, and cell-cycle regulators such as D-type cyclins and p27 are involved. Glucocorticoid and metabolic pathways also influence skeletal cell populations.
Can CRISPR be used to study negative regulation of osteoclast proliferation?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models can test causal roles of candidate genes in limiting osteoclast proliferation.
What diseases are linked to dysregulated osteoclast proliferation?
Excessive osteoclast activity contributes to bone loss, and models such as ovariectomy-induced bone loss are used to study skeletal cell fate interventions.
What experimental methods measure osteoclast proliferation?
Proliferation assays, flow cytometry, immunoblotting for D-type cyclins and p27, and signaling assays for Akt and NF-kappaB are commonly used.
Is Hippo-YAP/TAZ signaling involved in osteoclast proliferation control?
Hippo-YAP/TAZ signaling has an emerging role in musculoskeletal disorders and can influence skeletal cell proliferation and differentiation, making it a candidate pathway for further study.
Conclusion
GO:0090291, negative regulation of osteoclast proliferation, defines the processes that restrain osteoclast multiplication and thereby limit osteoclast population expansion. Key mechanistic insights come from studies of SHIP1-Akt signaling and cell-cycle control, as well as from work on c-Fms, NF-kappaB, and Lipocalin-2. Systemic and emerging pathways, including glucocorticoid signaling, metabolic regulation, and Hippo-YAP/TAZ, add further layers of control. CRISPR-based knockout, point-mutation, knock-in, and overexpression models provide direct ways to test candidate negative regulators and to advance understanding of bone homeostasis and disease.
References
- 1. Stegen S et al.. 2024. Metabolic regulation of skeletal cell fate and function.. Nat Rev Endocrinol 20(7):399-413 PMID: 38499689
- 2. Han J et al.. 2024. Emerging role and function of Hippo-YAP/TAZ signaling pathway in musculoskeletal disorders.. Stem Cell Res Ther 15(1):386 PMID: 39468616
- 3. Roodman GD. 2006. Regulation of osteoclast differentiation.. Ann N Y Acad Sci 1068:100-9 PMID: 16831910
- 4. Shen G et al.. 2020. Foxf1 knockdown promotes BMSC osteogenesis in part by activating the Wnt/β-catenin signalling pathway and prevents ovariectomy-induced bone loss.. EBioMedicine 52:102626 PMID: 31981979
- 6. Komori T. 2016. Glucocorticoid Signaling and Bone Biology.. Horm Metab Res 48(11):755-763 PMID: 27871116
- 7. Kim HJ et al.. 2016. Deficiency of Lipocalin-2 Promotes Proliferation and Differentiation of Osteoclast Precursors via Regulation of c-Fms Expression and Nuclear Factor-kappa B Activation.. J Bone Metab 23(1):8-15 PMID: 26981515
- 8. Zhou P et al.. 2006. SHIP1 negatively regulates proliferation of osteoclast precursors via Akt-dependent alterations in D-type cyclins and p27.. J Immunol 177(12):8777-84 PMID: 17142780
